Pfizer decided to abort the clinical trial of its daily weight loss pill 'Danuglipron' after one patient in a trial showed signs of liver damage, likely to be caused by the drug.

Pfizer PFE announced that it is discontinuing the development of danuglipron, its investigational oral GLP-1 receptor agonist (GLP-1 RA), which is being developed to treat obesity. The decision ...

The FDA and the maker of the popular diabetes and weight loss drug Ozempic are warning people not to use counterfeit semaglutide 1.0 milligrams — the Ozempic injection — found in the U.S. drug supply ...

BMO Capital Markets analyst Evan Seigerman said Pfizer’s discontinuation of its GLP-1 pill sends the company back to the starting block as its other obesity drugs are all in the early stages of ...

Mounjaro, a once-weekly injection approved by India's drug regulator, is priced at 4,375 rupees ($50.86) for a 5 milligram ...

The drugmaker said Tuesday that it would stop studying danuglipron after a participant in one of its trials experienced a ...

Pfizer on Monday announced it is halting development of a daily weight loss pill after one patient experienced a liver injury ...

Pfizer’s announcement that it will stop developing its oral weight-loss drug gave shares of Wegovy maker Novo Nordisk and ...

Pfizer is stopping development of its experimental oral GLP-1 drug for obesity, the company announced Monday, after a patient ...

The drugmaker said one patient became ill after being treated with its experimental weight-loss drug, danuglipron.

Viking Therapeutics enjoyed a nice share rally on the news that rival Pfizer is discontinuing obesity candidate danuglipron.